Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
BIIB · against 72 other Healthcare companies of similar size
Ranked #30 of 73 · scores higher than 60% of peers
Bars: peers in each 10-point band of the valuation score15 peers with a valuation score of 60–69, including BIIB · Click a bar to see the companies
Mainly thanks to its free cash flow yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | BIIB | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 69 reported | 2.3% | 2.9% | 32% | 30% | |
| EBITDA yieldHigher is better · 74 reported | 7.7% | 5.4% | 78% | 50% | |
| Free cash flow yieldHigher is better · 51 reported | 6.8% | 3.8% | 86% | 20% | |
| Book yieldHigher is better · 69 reported | 51.3% | 20.1% | 87% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.5B USD | 95 | 60 | |
| 2 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 3 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 4 | 45.9B USD | 84 | 61 | |
| 5 | 34.3B USD | 83 | 57 | |
| 26 | 225.2B CNY (≈$31.5B) | 64 | 63 | |
| 26 | 193.6B HKD (≈$24.8B) | 64 | 78 | |
| 26 | 50.2B USD | 64 | 49 | |
| 29 | 28.7B USD | 63 | 52 | |
| 30 | 36.8B USD | 61 | 46 | |
| 31 | 21.4B USD | 60 | 67 | |
| 31 | 43.2B USD | 60 | 45 | |
| 33 | 35.0B USD | 59 | 52 | |
| 33 | 16.7B CHF (≈$19.2B) | 59 | 47 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score